Pharmacy and Pharmaceutical Sciences Commons^™

Pacific Rxtracts - September 2026, Pacific Rxtracts

Pacific RxTracts

Articles

• Efficacy of Daraxonrasib Versus Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (Breaking News)
• A Multi-Drug, All-Age Unified PopPK Model for Aminoglycoside Dosing (General News)
• Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence (Cardiology)
• Low-Dose Hydrocortisone and Cognition in Women With HIV (Endocrine)
• Rethinking Pediatric Propofol Limits in the Absence of PRIS (Pediatrics)
• Eptinezumab in Chronic Migraine and Medication Overuse Headache: The RESOLUTION Trial (Neuropsychology)
• Ropeginterferon alfa-2b-njft Treatment in Essential Thrombocythemia: Mutation-Stratified Outcomes from EXCEED-ET (Oncology)
• Respiratory Syncytial Virus Vaccine Effectiveness in Medicare Beneficiaries Residing in Nursing Homes (Infectious Disease)
• Conclusive Evidence in Support of Amoxicillin …

Pacific Rxtracts - August 2026, Pacific Rxtracts

Pacific RxTracts

• Articles:
• FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
• Bemotrizinol: First FDA-Approved Sunscreen Ingredient in 20 Years
• Effects of Mavacamten in Hypertrophic Cardiomyopathy
• Small Increase in Bleeding Risk With Immediate Intensive Statin Therapy and Dual Antiplatelet Therapy in Mild Ischemic Stroke
• Retatrutide for Type 2 Diabetes: The TRANSCEND-T2D-1 Phase 3 Trial
• Reimagining Insulin Therapy: Clinical Impact of CagriSema in REIMAGINE-3
• FDA Approval of Veligrotug-vvze Establishes a New IV Biologic Option for TED
• Novel Oral GLP-1 Receptor Agonist HRS-7535 Shows Promising Results in Type 2 Diabetes
• FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
• Pockets of …

Pacific Rxtracts - July 2026, Pacific Rxtracts

Pacific RxTracts

Articles:

• Tribute: In Memory of Evan Le
• Redefining Influenza Prevention: Phase 3 Trial of an mRNA Influenza Vaccine
• Risk of Non-Vitamin K Anticoagulants in Atrial Fibrillation
• Oral Semaglutide and Cardiovascular Risk: Expanding Its Role in High-Risk Patients
• Baxdrostat for Resistant Hypertension: The Bax24 Phase 3 Trial
• SGLT2 Inhibitors Shown to Normalize Blood Pressure in Patients with Type 2 Diabetes
• Brolucizumab: A New Vision for Treating Proliferative Diabetic Retinopathy
• Mavacamten Comes of Age: FDA Expands Treatment Options for Adolescent Hypertrophic Cardiomyopathy
• Children and Adolescent CKD Management: New Evidence Supports RAAS Inhibitors as First-Line Therapy
• Comparing Survival Outcomes of CDK4/6 Inhibitors plus …

Pacific Rxtracts - June 2026, Pacific Rxtracts

Pacific RxTracts

Articles:

• FDA Approves First Non-Antipsychotic Drug for Patients with Alzheimer’s Disease Agitation
• FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis
• Lunsotogene Rings in a New Era of Gene Therapy for Hearing Loss
• Sex Differences in Breakthrough Stroke Outcomes Despite Oral Anticoagulation for Atrial Fibrillation
• Asundexian for Secondary Prevention After Ischemic Stroke or TIA
• Marstacimab Prophylaxis in Hemophilia A/B with Inhibitors: A New Purpose
• FDA Approves First-in-Class Weekly Anifrolumab Autoinjector for Systemic Lupus Erythematosus 
• Cemdisiran in Generalized Myasthenia Gravis
• Medicare’s Impact on Early Sepsis Management and Discharge to Home
• Maralixibat Shows Broader Therapeutic Benefit for Children with Alagille Syndrome 
• Reaching the Littlest …

The Influence Of Prosthetic Obturators On Quality Of Life In Individuals With Maxillectomy Defects, Minseok Kim

Oral Health

Abstract

Introduction: In recent years, there has been a growing focus on understanding the impact of oral cancer on patients' quality of life. Prosthetic rehabilitation techniques, such as maxillary obturators, often in conjunction with reconstructive surgery, have emerged as interventions to address the challenges posed by post-maxillectomy abnormalities.

Objective: This study aims to systematically review and evaluate the effectiveness of maxillofacial prosthetic rehabilitation using obturators in enhancing the quality of life of patients following maxillectomy.

Methodology: Systematic review of identified literature spanning the timeframe from 2000 to 2020 was used. The comprehensive search encompassed widely recognized databases including PubMed, …

Pacific Rxtracts - April 2026, Pacific Rxtracts

Pacific RxTracts

Articles:

• LAMA‑LABA Inhalers in COPD
• Another Potential Indication for Dupilumab: Chronic Spontaneous Urticaria
• Clinical Pharmacist‑Led Tobacco Treatment and Contingency Management in Patients With HIV
• FDA Approves First TYK2 Inhibitor for Adults With Active Psoriatic Arthritis
• Oral PCSK9 Inhibition with Enlicitide: A New Frontier in Lipid‑Lowering Therapy
• Lerodalcibep‑liga, Novel PCSK9 Inhibitor for the Management of Hypercholesterolemia
• Pharmaceutical Grade Cannabidiol for Myocardial Recovery in Acute Myocarditis
• Berberine Shows Limited Impact on Visceral and Liver Fat in MASLD Trial
• Comparative Outcomes of Orforglipron and Oral Semaglutide in Adults with Type 2 Diabetes
• Battling Pediatric Episodic Migraines – FDA Expands Approval of Fremanezumab
• Navepegritide …

Pacific Rxtracts - March 2026, Pacific Rxtracts

Pacific RxTracts

Articles:

• FDA Approves Zycubo as First Treatment for Menkes Disease
• A Step Toward New Lung Treatment - FDA Expands Nerandomilast Approval
• Olezarsen for Severe Hypertriglyceridemia and Pancreatitis Prevention
• Increasing Accessibility of Treatment for Hepatitis C Through Telemedicine
• Efficacy of a Shortened Romosozumab Therapy followed by Denosumab in Postmenopausal Osteoporosis
• Renal Outcomes of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in T2D
• Plozasiran, A Novel Therapy for Familial Chylomicronemia Syndrome
• Incretin Agonists and Reduced CPAP Use in Obesity-Related Obstructive Sleep Apnea
• Icotrokinra: A Novel Oral Therapy for Plaque Psoriasis
• Omega-3 Fatty Acids in Pediatric Major Depressive Disorder: Limited Benefit as Adjunctive Therapy …

Pacific Rxtracts - February 2026, Pacific Rxtracts

Pacific RxTracts

Articles:

• Reducing Proteinuria – FDA Accelerates Approval of Sibeprenlimab
• FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
• New First-Line Digital Treatment for Generalized Anxiety Disorder
• Ammoxetine: A Potential New Antidepressant For Major Depressive
• Extended-Release Buprenorphine Dosing in Individuals With High-Risk Opioid Use
• Managing Acute Agitation Without Injections: Oral Medications in the ED
• Prescription Stimulant Continuation in Pregnancy and Birth Outcomes
• Zoliflodacin - A New Treatment For Gonorrhea
• Intranasal Dexmedetomidine for Postoperative Sleep Quality After Gynecologic Laparoscopy
• FDA Approves Depemokimab, the First Twice-Yearly Biologic for Severe Eosinophilic Asthma Cancer Care
• Engineering Allogeneic CD7-Targeted CAR-T Cells Through Targeted Base …

Evaluating The Analgesic Activity Of The Ethanolic Leaf Extract Of Ipomoea Aquatica (Convolvulaceae), Blessy H. Vale, Lenny Shai Somer, Julie Mae Suico, Roselle L. Remulta, Junnin Gay Garay

Pacific Journal of Health

Ipomoea aquatica, commonly known as water spinach, is a leafy vegetable widely consumed in tropical and subtropical regions for its nutritional benefits. This study investigated the potential analgesic activity of the ethanolic leaf extract of I. aquatica, as no prior scientific evidence supports its role in acute pain management. Male Swiss albino mice were used in an acetic acid-induced writhing test, with aspirin as the positive control and plain normal saline solution (PNSS) as the negative control. The extract was administered at low, medium, and high doses. In the writhing test, I. aquatica significantly inhibited the writhing response …

Pacific Rxtracts - December 2025, Pacific Rxtracts

Pacific RxTracts

Articles:

• FDA Approves Nerandomilast: A New Era in Idiopathic Pulmonary Fibrosis Treatment
• Brand New Approach to Addressing the Unmet Need of Cholestatic Pruritus
• Prep for Success with Lactulose
• Caution with Reported Allergies: Increased Risk of Surgical Site Infection with Non-β-Lactam Antibiotics
• Eltrombopag Redefines Treatment for Newly Diagnosed Pediatric ITP Combination for Extensive-Stage Small Cell
• Advancing Treatment for HER2-Positive Breast Cancer: Trastuzumab Deruxtecan plus Pertuzumab
• Comparison in Efficacy of Abiraterone and Enzalutamide in US Veterans with mHSPC
• Revumenib: A First-in-Class Menin Inhibitor for Relapsed or Refractory Acute Myeloid Leukemia
• Ziftomenib: A Menin Inhibitor Redefining Precision Therapy in NPM1-Mutated AML
• The Future …

Pacific Rxtracts - November 2025, Pacific Rxtracts

Pacific RxTracts

This issue features updates on the FDA approval of Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis; the early success of stem cell-derived islet therapy in type 1 diabetes; and the use of oral Palonsify in the management of acromegaly.

You will also find additional highlights across several specialties such as endocrinology, oncology, neuropsychology, and infectious disease. Each article provides valuable insights to help you stay informed on the latest developments in pharmacy, and we encourage you to give them a read.

Pharmacist Quality Of Work-Life During Covid-19 Pandemic In Cagayan De Oro, Junnin Gay Labrigas Garay, Rugine Riel D. Barsobia, Zoe Kyra Evasco, Bonnie Louise Elorde

Pacific Journal of Health

During the COVID-19 pandemic, pharmacists have been one of the most accessible healthcare workers working in the frontline providing the medication and drug needs of patients. Their roles and responsibilities in work expanded and to some redefined as the pandemic hit. Adjustments in their work, and workplaces were also implemented in adherence to the pandemic situation. The quality of work life of frontline pharmacists were affected because of the changes brought by the pandemic. A descriptive qualitative study design was used to determine the pharmacist’s quality of work-life during the COVID-19 pandemic in Cagayan de Oro City. The place was …

Pacific Rxtracts - October 2025, Pacific Rxtracts

Pacific RxTracts

Articles:

• The Resurgence of Cardiac Glycosides in Heart Failure
• Wayrilz: New Breakthrough for Persistent or Chronic Immune Thrombocytopenia
• Atrasentan: An Emerging Therapy in IgA Nephropathy
• The Second FDA-Approved MASH Treatment
• New Pharmacist-Driven Calcitonin Protocol Delivers Cost Savings in Hypercalcemia of Malignancy Care
• Baxdrostat Offers Hope for Patients with Resistant Hypertension
• Challenging the Norm: Anticoagulant Discontinuation is Safe Postablation
• Olezarsen: Redefining Triglyceride Control Through APOC3 Inhibition
• Semaglutide and Tirzepatide Linked to Increased Risk of Vision Disorders
• At Last, a Step Forward in Gastric and GEJ
• Tarlatamab: A Breakthrough in Relapsed Small Cell Lung
• Expanded FDA Approval for Darolutamide
• Linvoseltamab: Redefining Multiple …

Pacific Rxtracts - August 2025, Pacific Rxtracts

Pacific RxTracts

Articles:

• Ready. Set. Infuse: TYZAVAN Brings Vancomycin Closer to the Bedside
• ENFLONSIA: A New Era in RSV Prevention for Infants
• A Shot for Peace of Mind: Can Yeztugo Eliminate the Risk of Contracting HIV?
• Ekterly: The First Orally Administered On-Demand HAE Treatment
• Autologous Chimeric Antigen Receptor CAR T cell Immunotherapy Risk Evaluation and Mitigation Strategies Removed
• Early Tirofiban Intervention Lowers Likelihood of Disability Post-Stroke
• Obicetrapib in High Risk Patients: A New Chapter in Cholesterol Management
• Lorundrostat for Uncontrolled Hypertension: Phase 3 Clinical Trial
• The Potential of Cagrilintide/Semaglutide (CagriSema) in Weight Management
• The Unfortunate Link Between GLP-1 RAs and Neovascular Macular …

Pacific Rxtracts - July 2025, Pacific Rxtracts

Pacific RxTracts

Articles:

• First Blood Test Approved For the Diagnosis of Alzheimer’s Disease
• Rare Withdrawal Reaction Prompts Label Update for Common Antihistamines
• FDA Approves SUSVIMO: Shifting Diabetic Retinopathy Treatment from Monthly Injections to Continuous Therapy
• Battle Against Resistant Hypertension
• Two Is Better than One: Obicetrapib and Ezetimibe, a Novel Combination Pill for High Cholesterol
• Histo-blood Group ABO System Transferase and Venous Thromboembolism Risk
• GLP-1 Agonists and Thiazolidinedione Combination Therapy in Type 2 Diabetes
• Dual Pathway Targeting in Type 2 Diabetes: Exploring the Synergy of GLP1- RAs and SGLT2-inhibitors
• Two Vaccines, One Shot: Combined Immunizations Against COVID-19 and Influenza
• Mirikizumab: A New Frontier …

Determination Of The Anti-Inflammatory Activity Of The Methanolic Leaf Extract Of Strelitzia Reginae (Strelitziaceae), Lyannah Deign Hearty Delantar Hinol, Miflor De La Cerna, Decethree Gocela, Aymah Macalonto, Junnin Gay Garay

Pacific Journal of Health

Inflammation is a biological response that, if unregulated, can contribute to various health disorders. The search for new anti-inflammatory agents has led researchers to explore the medicinal potential of Strelitzia reginae, commonly known as the Bird of Paradise. This study aimed to determine the phytochemical composition and anti-inflammatory activity of the methanolic leaf extract of S. reginae. Phytochemical screening confirmed the presence of alkaloids, flavonoids, terpenoids, phenols, saponins, and steroids, while tannins were absent. The Croton Oil-Induced Ear Edema Assay in Swiss albino mice was used to assess anti-inflammatory activity, with Indomethacin as a positive control. Acute oral …

Pacific Rxtracts - June 2025, Pacific Rxtracts

Pacific RxTracts

Articles:

• Atzumi Receives FDA Approval as First Nasal Powder DHE for Migraine Treatment
• IMAAVY: First and Only FDA-approved Neonatal Fc Receptor Inhibitor for gMG
• New Prophylactic Treatment Approved for Hemophilia A or B, With or Without Factor Inhibitors
• Cytisinicline: The Next Smoking Cessation Aid
• FDA Approves Dupilumab for the Management of Chronic Spontaneous Urticaria
• Study Shows Promise in Combining Behavioral Treatment with Phentermine
• Metformin for Osteoarthritis
• A New Direction in Atopic Dermatitis Treatment
• Orforglipron: A Potential Oral Alternative to Injectable GLP-1 Agonists
• Beyond GLP-1s: MariTide’s Dual Mechanism in Weight Loss Therapy
• Atrasentan Gains FDA Approval to Combat Proteinuria in Primary …

Pacific Rxtracts - April 2025, Pacific Rxtracts

Pacific RxTracts

Articles:

• FDA Approves Miudella: First New Hormone-Free IUD in Over 40 Years
• First Treatment for Cerebrotendinous Xanthomatosis Approved
• Presepsin: A New Biomarker for Assessing Cardiovascular Disease
• New Insights into Severe NOWS Prediction
• Myasthenia Gravis: Nipocalimab, a Potential Add-on Therapy
• ARF/ARDS Concern with Trimethoprim-Sulfamethoxazole in Youth
• Hormone Replacement Therapy: Beneficial for Managing Menopausal Symptoms Long-Term?
• Esketamine Shows Promise in Preventing Postpartum Depression After Cesarean Delivery
• From One Week to One Hour: FDA Approves Label Changes for Sublocade Rapid Induction in Patients with Moderate to Severe Opioid Use Disorder
• Repurposing Semaglutide: A Novel Approach to Alcohol Use Disorder
• Treating Neuropathic Pain: Pregabalin …

Pacific Rxtracts - March 2025, Pacific Rxtracts

Pacific RxTracts

Articles

• Naloxone Extended-Release System Discovered at the University of the Pacific
• FDA Approval for Unresectable/ Metastatic Breast Cancer
• Journavx (Suzetrigine): A New Era in Pain Management
• New Treatment Approved for Congenital Adrenal Hyperplasia
• Optimal DAPT Strategy? A Promising Approach for Post-PCI Care
• Benefit of SGLT2 Inhibitors in Preventing Contrast-Induced Kidney Injury
• Dark Chocolate and Type 2 Diabetes: A Sweet Connection?
• Confirming Palbociclib’s Safety in Liver Impaired Patients
• Aztreonam-avibactam, a Promising Therapeutic for Gram-Negative Bacterial Infections
• The Future is Now: LBP-EC01, a Genetically Enhanced Bacteriophage for UTIs
• The Safety and Efficacy Profiles of Short-Term Duration Oral Regimens for Rifampin-Resistant TB
• A …

Pacific Rxtracts - February 2025, Pacific Rxtracts

Pacific RxTracts

Articles:

• Revolutionizing Hypertension Screening: AI-Enhanced ECG as a Proactive Healthcare Tool
• Breaking News:
  • New Indication for Zepbound
  • FDA Approves Injectable Nivolumab: A New Era for Opdivo in Cancer Care
  • Stromal Stem Cells for Steroid-Refractory Acute Graft-vs-Host Disease
• Cardiology:
  • Beta Blocker vs. Verapamil Therapy for Hypertrophic Cardiomyopathy
• General News:
  • Prolactin-Increasing Antipsychotics Increase the Odds of Breast Cancer
  • Hope for a Cytomegalovirus Vaccine: mRNA-1647
  • Targeting IL-13: Innovations in the Treatment of Atopic Dermatitis
  • Beyond Opioids: Multimodal Pain Management in Colorectal Surgery
  • A Nanomaterial Dosage Form for Mupirocin
  • Guselkumab, a potential drug for Ulcerative colitis
• Neuropsychiatry:
  • Dextromethorphan for Depression: More For Just a …

Effects Of Cross-Sex Hormone Therapy (Csht) On Aortic Reactivity And Metabolic Parameters In Gonadectomized Male And Female Rats, Rifat Ara Islam

University of the Pacific Theses and Dissertations

With the rising awareness, the number of individuals identifying themselves as transgender in the US is increasing over the years. Cross-sex hormone therapy (CSHT) may alter cardiometabolic parameters leading to the increased risk of cardiovascular diseases (CVD) in transgender population. However, the underlying mechanisms of impaired cardiovascular functions in transgender female (male to female, MtF) or transgender male (female to male, FtM) individuals are not well documented. This study was undertaken to examine the effects of 17β-estradiol (E2)- and testosterone propionate (Tes)-treatment on key cardiometabolic parameters and aortic reactivity in castrated (CAS) male and ovariectomized (OVX) female Sprague Dawley (SD) …

Pacific Rxtracts - December 2024, Pacific Rxtracts

Pacific RxTracts

Articles

• Attruby: A Promising Treatment for Transthyretin Amyloid Cardiomyopathy
• Triple Threat: GMRx2, An Emerging Low-Dose Triple Pill For Hypertension
• New Treatment for Hemophilia A or B
• Breaking the Placebo Barrier: FDA Review Challenges Effectiveness of Popular Decongestant
• Exploring Bempedoic Acid: Potential Benefits for Statin-Intolerant Patients and Liver Health
• The Flu Vaccine: Meeting You Where You Are
• Unique Application of Statins for Radiotherapy-Induced Cardiotoxicity
• One Shot, Two Solutions: How Semaglutide Combats Obesity and Knee Osteoarthritis

Pacific Rxtracts - November 2024, Pacific Rxtracts

Pacific RxTracts

Articles:

• Semaglutide: Hope for Alzheimer's Prevention
• A New Potential Indication for Tirzepatide
• New Drug Target for Treating Schizophrenia
• The Prevent Calculator: Does America Have A Statin Problem?
• Weighing the Risks vs. Benefits of Liraglutide for Children
• CD19-CAR T-Cell Therapy: Revolutionizing Autoimmune Disease Treatment
• Conceived with Technology, Born with Risks: ART Babies and Heart Defects
• Machine Learning and Neural Networks: The Future of Clinical Pharmacy?. .

Pacific Rxtracts - October 2024, Pacific Rxtracts

Pacific RxTracts

Articles

1. First Nasal Spray for Anaphylaxis Approved
2. Statins: The Unexpected Therapeutic Benefits You Didn’t Know About
3. Is COVID Driving Us Mad? The Mental Toll on the Unvaccinated vs. Vaccinated
4. Acetaminophen’s Effects on Positive Empathy
5. Semaglutide: More Than Meets The Eye
6. RSV: Complications and New Therapies
7. Contribution of Calcium Channel Blockers and Selective Serotonin Reuptake Inhibitors to the Risk of Fractures

Antiseizure Properties Of Fenamate Nsaids Determined In Mature Human Stem-Cell Derived Neuroglial Circuits., Hamed Salmanzadeh, Robert F. Halliwell

School of Pharmacy Faculty Articles

Repeated and uncontrolled seizures in epilepsy result in brain cell loss and neural inflammation. Current anticonvulsants primarily target ion channels and receptors implicated in seizure activity. Identification of neurotherapeutics that can inhibit epileptiform activity and reduce inflammation in the brain may offer significant benefits in the long-term management of epilepsy. Fenamates are unique because they are both non-steroidal anti-inflammatory drugs (NSAIDs) and highly subunit selective modulators of GABA_A receptors. In the current study we have investigated the hypothesis that fenamates have antiseizure properties using mature human stem cell-derived neuro-glia cell cultures, maintained in long-term culture, and previously shown to …

Stevens-Johnson Syndrome From Combined Allopurinol And Angiotensin-Converting Enzyme Inhibitors: A Narrative Review, Isabella M. Fabian, Kirsten Maddox, Cameron Robicheaux, Rahib K. Islam, Ahmed Anwar, Bradley Dorius, Christopher L. Robinson, Adam M. Kaye, Giustino Varrassi, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D. Kaye

School of Pharmacy Faculty Articles

Stevens-Johnson syndrome (SJS) is a severe and potentially debilitating skin reaction frequently related to medication use. Allopurinol and angiotensin-converting enzyme (ACE) inhibitors are commonly prescribed medications for prevalent health conditions worldwide, and their interaction associated with SJS warrants further investigation. A comprehensive literature search was performed to investigate cases as studies related to SJS occurring in patients with concomitant use of allopurinol and ACE inhibitors. We identified case reports and studies detailing hypersensitivity reactions, including SJS, attributed to a combination of allopurinol and ACE inhibitors. Despite the drug-drug interactions or lack thereof seen in patient populations, there is no definitive …

Zeitlin’S Top 200 Dental Deckades (January 2024), Benjamin D. Zeitlin

Pacific Open Texts

Pharmacology courses in any institution are information intensive with a constant, high volume of new material. With that in mind, the standards that the American Dental Education Association set for Pharmacology include that: “the student must identify the influences drugs taken for non-dental purposes may have on a proposed treatment (…) and the student must recognize therapeutic agents used in the routine practice of clinical dentistry.” This requires that students at a minimum, recognize common drugs and know their major implications for dental therapy.

This learning tool has been created to address the drug recognition aspect of that standard.

See …

Elaboration Of Diquinanes To Access Trifunctional Angular Triquinanes And Designed Dna Polymerase Α Inhibitors, Spencer M. Webber

University of the Pacific Theses and Dissertations

Natural products are of great significance to the pharmaceutical industry in the development of new drugs. Diquinane or bicyclo[3.3.0]octane is a conspicuous structural unit existing in the carbo-frameworks of a wide range of natural products such as alkaloids and terpenoids. These diquinane-containing molecules not only exhibit intriguing architectures, but also showcase a broad spectrum of significant bioactivities, which draw widespread attention from the global synthetic community. A more specific group of compounds containing a diquinane moiety with one extra 5-membered ring are called the angular triquinanes.In this work, we have developed a general synthetic scheme to the angular triquinanes. We …

Development Of Nano Formulations Of Lipophilic Platinum Complexes Against Lung Cancer, Zizhao Xu

University of the Pacific Theses and Dissertations

Lung cancer remains a leading cause of death worldwide and urges the development of more effective and safer treatment options. Conventional platinum-based drugs like cisplatin, while effective, are associated with significant systemic toxicity, particularly nephrotoxicity. Nano formulations, such as liposomal and micellar delivery systems, represent a promising approach to enhance the anticancer activity and reduce the toxicity of platinum complexes.

This study develops and evaluates novel miriplatin-loaded nano formulations for lung cancer therapy. We prepared and screened various liposomal and micellar formulations of miriplatin by either thin-film hydration or co-solvent evaporation, which identified a number of formulations with appropriate sizes …

An Empirical Predictive Model For Determining The Aqueous Solubility Of Bcs Class Iv Drugs In Amorphous Solid Dispersions, Sridivya Raparla

University of the Pacific Theses and Dissertations

Poor aqueous solubility persists as a significant challenge in the pharmaceutical industry.Ongoing research aims to enhance the solubility of drugs to deliver them more effectively. Amorphous solid dispersion (ASD) is a widely used solubility enhancement technique. The absence of a specific model to predict compound solubility from ASDs resulted in a trial-and- error approach to studying solubility enhancement and makes it a laborious and time-consuming process. Predictive models could streamline this process and accelerate the development of oral drugs with improved aqueous solubilities. This study aimed to develop a predictive model to estimate the solubility of a compound from the …